Orchestra Biomed (NASDAQ:OBIO): Investor Relations Program

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies.

Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops.


  • LifeSci engaged following a global strategic partnership with Terumo announced in June 2019
  • Strengthen the equity story and position the Company to secure additional strategic global partnerships
  • Raise visibility amongst global institutional investors, HNWI’s and strategics
  • Prepare the market for Orchestra to complete a Series D financing in H2 2022
  • Company listing on NASDAQ
  • Secure investment banking conference invitations and increase interest in the story amongst research analysts


  • Strategic Collaboration with MedTronic for the development of BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients secured in 2022
  • Successful $110M Series D financing; Terumo, MedTronic, RTW Investments and Perceptive Advisors all participated in the round
  • Successful listing on NASDAQ via combination with special-purpose acquisition company, Health Sciences Acquisitions Corp. 2, with a redemption rate at less than 50% and cash runway into 2026 secured